DDInter1355 DDInter1658
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Oxaliplatin {u} (Compound) binds {v} (Gene) ATP7B
Oxaliplatin {u} (Compound) is included by {v} (Pharmacologic Class) Platinum-containing Compounds
Oxaliplatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaprozin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Floxuridine
Oxaliplatin {u} may lead to a major life threatening interaction when taken with {v} Escitalopram
Oxaliplatin {u} may lead to a major life threatening interaction when taken with {v} Dofetilide
Oxaliplatin (Compound) binds ATP7B (Gene)
Oxaliplatin (Compound) is included by Platinum-containing Compounds (Pharmacologic Class)
Oxaliplatin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine
Oxaliplatin may lead to a major life threatening interaction when taken with Escitalopram
Oxaliplatin may lead to a major life threatening interaction when taken with Dofetilide